Please note that the program was recorded before nivolumab was approved on August 19, 2021, for the adjuvant treatment of people with urothelial carcinoma who are at high risk of recurrence after radical resection. The approval is supported by results of a randomized, double-blind, placebo-controlled trial showing a statistically significant improvement in disease free survival observed in both the intent-to-treat patient cohort and in those whose tumors express PD-L1 ≥1%. The results of the clinical trial supporting this approval also led to the conversion of nivolumab’s accelerated approval to regular approval in advanced/metastatic UC.

Immunotherapy of Bladder Cancer: Integrating New Biomarkers and Treatment Guidelines into Clinical Practice


Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and of Urology
Co-Director, Signal Transduction Research Program
Yale School of Medicine, Yale Cancer Center
New Haven, CT


Arjun V. Balar, MD
Assistant Professor of Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter
Cancer Center
NYU Langone Health
New York, NY


This activity will cover the treatment and management of patients with bladder cancer.


This activity is designed to meet the educational needs primarily of urologists and other clinicians involved in the treatment of patients with bladder cancer.


On completing the program, attendees should be able to:

  • Critically evaluate the advantages and drawbacks of various CPGs for treating bladder cancer (BC), and apply the most useful and practical recommendations in clinical practice
  • Understand the molecular pathways involved in the development and progression of MIBC and NMIBC, and adopt diagnostic, predictive, and prognostic biomarkers into clinical practice, as they are perfected and become widely available for clinical use
  • Implement tactics for the successful management of irAEs experienced by BC patients treated with ICIs and other immunotherapies, allowing uninterrupted courses of treatment and minimizing diminishment of patients’ QOL


Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


Purpose: This program would be beneficial for nurses involved and/or interested in the therapeutic management of patients with bladder cancer.
CNE Credits: 1.0 ANCC Contact Hour


Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


Faculty Member Disclosure
Daniel P. Petrylak, MD Daniel P. Petrylak reports that he serves as a consultant for Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Incyte, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Roche, Seattle Genetics, and Urogen. He has also received grant support from Ada Cap (Advanced Accelerator Applications), Agensys Inc, *Astellas, AstraZeneca, *Bayer, BioXcel Therapeutics, Bristol-Myers Squibb, Clovis Oncology, Eisai, *Eli Lilly,*Endocyte, Genentech, *Innocrin, MedImmune, Medivation, Merck, Mirati,*Novartis, Pfizer, *Progenics, Replimune, Roche, *Sanofi Aventis, and Seattle Genetics. Dr. Petrylak also had ownership interest/investment in Bellicum (sold 7/2020), Tyme (sold 10/2019).
Arjun Balar, MD Dr. Balar reports that he serves as a consultant/advisor for Genentech, Incyte, Janssen, Merck, Pfizer, AstraZeneca/Medimmune, Nektar, Seattle Genetics, and Immunomedics. He has also done contracted research for Genentech, Nektar, Merck, AstraZeneca/Medimmune, Seattle Genetics, and Immunomedics. Dr. Balar has done speaking engagements for Genentech, Merck, and AstraZeneca/Medimmune. He has served on Steering Committees/Scientific Advisory Committees for Merck and Nektar. He receives equity and serves as a Scientific Advisory Board Member for EpiVax Oncology.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
Angela L. Davis, PhD, Director of Medical & Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.


Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.


There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete posttest and evaluation form online.

You will receive your certificate as a downloadable file.


Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: May 7, 2021


Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

Healthcare Business Review Award

We are thrilled to announce that we have been recognized as one of the Top 10 Health Education Services Providers by Healthcare Business Review!

This award is both an honor and a testament to our cumulative dedication to providing the best continuing medical education (CME) services to HCPs across the globe. We are proud to be part of this distinguished group and look forward to continuing to have MLG be one of the best CME providers in the country.

Thank you to Healthcare Business Review for this recognition and for shining a light on the importance of accurate and accessible healthcare education.

#TopHealthEducationProvider #MedLearningGroup #HealthcareBusinessReview #MedicalEducation

Best of America Small Business Awards
Best Website

The Best of America Small Business Website award recognizes the best website launched by a small business since 2021. Technology is a key growth enabler for small businesses. The best in tech track recognizes small businesses as experts in technology and innovation from innovators, app developers, and website creators. Visit our award-winning Ophthalmology and Optometry web portal:

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.